Gilead Sciences Britain Usa Canada EU News Treatment Gilead Sciences Britain Usa Canada EU

Twice-Yearly HIV Treatment Approved for Those With Drug Resistance

Reading now: 809
www.advocate.com

The U.S. Food and Drug Administration approved the drug Sunlenca (lenacapavir), produced by Gilead Sciences, in combination with other antiretrovirals for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) adults with multi-drug resistant (MDR) HIV-1 infection.Sunlenca offers a new, twice-yearly treatment option for HIV-positive adults that is not adequately controlled by their current regimen.“Today’s approval ushers in a new class of antiretroviral drugs that may help patients with HIV who have run out of treatment options,” Debra Birnkrant, M.D., said in a press release from the FDA. “The availability of new classes of antiretroviral medications may possibly help these patients live longer, healthier lives.”Daniel O’Day, Chairman and Chief Executive Officer of Gilead Sciences, echoed the statement saying, “This news is an important milestone in the work to help end the HIV epidemic as Sunlenca is now the only FDA-approved twice-yearly treatment for people with multi-drug resistant HIV.”The approval for Sunlenca is supported by data from the Phase 2/3 CAPELLA trial.

Participants had previously undergone previous treatment with a median of nine antiretroviral medications.The review and approval for Sunlenca as a medication went through the FDA Breakthrough Therapy Designation intended to expedite the development and review of new drugs that may provide substantial improvement over available therapy.The United States, United Kingdom, Canada and the European Union (EU) are the only countries to have approved the use of lenacapavir, whether alone or in combination.

Read more on advocate.com
The website meaws.com is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

19.01 / 04:27
News hospital Star Elm Street Star Mark Patton Hospitalized With AIDS Complications, Seeks Help
Mark Patton, an American interior designer and out actor best known for his starring role on A Nightmare on Elm Street 2: Freddy’s Revenge, has been hospitalized due to AIDS-related ailments.A GoFundMe page was set up by Patton’s manger, Peter Valderrama, who apologized for a Chicago show Patton had to cancel due to the hospitalization. Writing that Patton “has been ill for quite some time now,” Valderrama noted they originally believed the sickness was the aftershocks of COVID and could be managed with some rest and recuperation.While Patton initially wanted to keep the news private, the cancellation of events prompted him to release the news in hopes he could find some help.The fundraiser notes that Patton is currently in a Mexican hospital (he owns and operates an art store with his partner in Puerto Vallarta) that is “completely overcome with COVID cases.” Communication at the hospital is a problem as staff speak little English, according to Valderrama.The fundraiser asks for donations to transport Patton to an American hospital in Mexico where he can receive “more specialized care in a safer setting.”A statement from Patton on the fundraiser page says, “Basically I am asking for help I will not be embarrassed… I just want to be healthy and at home with family.”Donations not only help with the transfer, but also help cover the $300 a day cost of the American hospital.
DMCA